Raymond James Downgrades Disc Medicine to Outperform, Announces $40 Price Target
Portfolio Pulse from Benzinga Newsdesk
Raymond James analyst Danielle Brill downgrades Disc Medicine (NASDAQ:IRON) from Strong Buy to Outperform with a new price target of $40.
April 01, 2024 | 2:39 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Disc Medicine downgraded from Strong Buy to Outperform by Raymond James with a $40 price target.
The downgrade from Strong Buy to Outperform suggests a positive yet more cautious outlook on Disc Medicine by Raymond James. The $40 price target indicates a belief in potential growth, but the downgrade may temper short-term expectations among investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90